<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">3866</id>
  <title>T3D3811</title>
  <common-name>Clofentezine</common-name>
  <description>Clofentezine is an acaricide used for the residual control of mites. It acts primarily as an ovicide, with some activity on early motile stages. Used on a wide range of crops – apples, pears, stone fruit, nuts, ornamentals, almonds etc. The main toxicological effects seen in studies in rats and dogs were hepatotoxicity and changes to the thyroid, including follicular hyperplasia. Clofentezine does not pose a high toxicity risk to humans.</description>
  <cas>74115-24-5</cas>
  <pubchem-id>73670</pubchem-id>
  <chemical-formula>C14H8Cl2N4</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point></melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility></solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure></route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity></mechanism-of-toxicity>
  <metabolism></metabolism>
  <toxicity>Oral (rat) &gt; 5200 mg/kg
Dermal (rat) &gt; 2100 mg/kg
Inhalation (rat) &gt; 0.89 (mg/l)</toxicity>
  <lethaldose></lethaldose>
  <carcinogenicity>Not listed by IARC.</carcinogenicity>
  <use-source>This is a man-made compound that is used as a pesticide.</use-source>
  <min-risk-level></min-risk-level>
  <health-effects>No adverse health effects attributable to clofentezine were detecte during medical surveillance between 1985 and 2004 in workers at a plant manufacturing clofentezine. The medical examination included an extensive physical examination (including height, body weight, skin, ear, nose and throat, and respiratory, nervous,  alimentary, reticulo-endothelial and cardiovascular systems, and locomotion) and specific tests for blood pressure and vision. The examination also included tests for hearing, lung function, urine analysis and blood tests when these were considered appropriate.  (Makhteshim Agan Industries Ltd, 2004). However, there is an increase of incidences of thyroid adenomas, adenocarcinomas, thyroid hyperplasia, agglomeration of colloid and thyroid hormones in rats receiving prolonged treatment of high dose of clofentezine.</health-effects>
  <symptoms></symptoms>
  <treatment></treatment>
  <created-at type="dateTime">2013-04-25T07:56:50Z</created-at>
  <updated-at type="dateTime">2026-03-27T00:11:00Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia></wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C18576</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>39315</chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id></ctd-id>
  <stitch-id></stitch-id>
  <drugbank-id></drugbank-id>
  <pdb-id></pdb-id>
  <actor-id></actor-id>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>ClC1=CC=CC=C1C1=NN=C(N=N1)C1=CC=CC=C1Cl</moldb-smiles>
  <moldb-formula>C14H8Cl2N4</moldb-formula>
  <moldb-inchi>InChI=1S/C14H8Cl2N4/c15-11-7-3-1-5-9(11)13-17-19-14(20-18-13)10-6-2-4-8-12(10)16/h1-8H</moldb-inchi>
  <moldb-inchikey>UXADOQPNKNTIHB-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">303.146</moldb-average-mass>
  <moldb-mono-mass type="decimal">302.01260169</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp></logp>
  <hmdb-id></hmdb-id>
  <chembl-id>CHEMBL17888</chembl-id>
  <chemspider-id>66321</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM002772</chemdb-id>
  <dsstox-id>DTXSID9023881</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00005836</susdat-id>
  <iupac nil="true"/>
  <moldb-polar-surface-area>51.56</moldb-polar-surface-area>
  <moldb-refractivity>103.8588</moldb-refractivity>
  <moldb-polarizability>29.020642375683046</moldb-polarizability>
  <moldb-rotatable-bond-count>2</moldb-rotatable-bond-count>
  <moldb-acceptor-count>4</moldb-acceptor-count>
  <moldb-donor-count>0</moldb-donor-count>
  <moldb-pka-strongest-acidic nil="true"/>
  <moldb-pka-strongest-basic>-4.6209100129222485</moldb-pka-strongest-basic>
  <moldb-physiological-charge>0</moldb-physiological-charge>
  <moldb-number-of-rings>3</moldb-number-of-rings>
  <moldb-alogps-logp>3.40</moldb-alogps-logp>
  <moldb-alogps-logs>-4.07</moldb-alogps-logs>
  <moldb-alogps-solubility>2.59e-02 g/l</moldb-alogps-solubility>
</compound>
